HIV infection is associated with persistent upregulation of PD-1, LAG-3, TIGIT and perhaps other checkpoint molecules, particularly on HIV-specific T cells. We hypothesize that simultaneous engagement of multiple targets via bispecific antibodies (BsAbs) will enhance anti-HIV efficacy compared to single or combination approaches.
Two BsAbs targeting the negative checkpoint receptors PD-1 & LAG-3 and PD-1 & TIGIT, as well as the corresponding monospecific antibodies, were developed. The secretion of 10 pro-inflammatory cytokines by PBMCs from HIV-infected subjects following stimulation with gag peptides in the presence of BsAbs or monospecific antibodies was quantified. Checkpoint receptor expression by HIV-specific CD8 T cells from infected individuals was evaluated. Assays to measure the ability of BsAbs to bind receptors in cis or trans were developed. Imaging flow cytometry combined with FRET was used to compare BsAb and monospecific antibody internalization.
We studied PMBCs from 26 HIV-infected individuals (18 treated and 8 untreated). As expected, HIV antigens stimulated the secretion of cytokines (IFNγ, IL-2, and TNFα); this effect was enhanced following BsAb co-treatment in a subset of individuals, with the impact more pronounced in untreated donors. About 1 in 3 of all subjects screened demonstrated increased IFNγ production in response to ex vivo BsAb treatment versus isotype control. IFNγ ex vivo responses were generally higher following BsAb-treatment as compared to monospecific antibody-treatment. As compared to total CD8 T cells, LAG-3 and TIGIT receptors were higher on PD-1-positive HIV-specific CD8 T cells from HIV-infected individuals. BsAbs demonstrated binding in both cis- and trans-orientation and were capable of internalization.
Previous studies in cancer and other fields have demonstrated a benefit of targeting multiple antigens simultaneously using BsAbs. Our experiments will inform the use of BsAbs versus a combination of bivalent antibodies for an immune checkpoint-targeting approach to treat HIV infection. In addition, the findings that BsAbs are capable of both cis-binding, trans-binding, and internalization are essential to understanding the therapeutic potential of BsAbs. Together this work provides a greater overall understanding of BsAb function and efficacy for immune checkpoint-targeting approaches in HIV infection.